Generated by AI
enVVeno Medical Corporation is a medical device company focused on developing bioprosthetic, tissue-based solutions for venous disease. The company’s current portfolio centers on the VenoValve, a surgical replacement venous valve designed for patients with deep venous chronic venous insufficiency, and enVVe, a non-surgical, transcatheter-based venous valve system under development. These products are intended to address valve failure in the deep venous system and support more effective blood flow in patients with chronic venous disorders. enVVeno Medical Corporation serves the broader vascular medicine market, where it aims to improve treatment options for conditions that can cause pain, swelling, and long-term circulatory problems. Based in Irvine, California and incorporated in 1999, the company remains a late clinical-stage player in specialized medical technology, with a business model centered on advancing implantable and minimally invasive venous care solutions.
Website70 Doppler
Irvine, CA, 92618
United States
The latest articles about NVNO.
CEO-led series gives investors the story - straight talk, no B., no corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the next episode hereIRVINE, CA / ACCESS Newswire / October 21, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the release of the third episode of its video series, "WTF with Rob Berman".
Summary of Apr 29's posts. Generated by AI.
Summary of Jan 30's posts. Generated by AI.
No summary yet.
Summary of Feb 20's posts. Generated by AI.
Investors talking about NVNO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.